Quoin Pharmaceuticals, Ltd.
QNRX
$6.60
-$0.5165-7.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.33M | 1.36M | 1.62M | 1.62M | 1.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.41M | 2.53M | 2.14M | 2.46M | 2.22M |
| Operating Income | -2.41M | -2.53M | -2.14M | -2.46M | -2.22M |
| Income Before Tax | -2.31M | -2.35M | -1.97M | -2.33M | -2.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.31M | -2.35M | -1.97M | -2.33M | -2.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.31M | -2.35M | -1.97M | -2.33M | -2.05M |
| EBIT | -2.41M | -2.53M | -2.14M | -2.46M | -2.22M |
| EBITDA | -2.38M | -2.50M | -2.11M | -2.43M | -2.19M |
| EPS Basic | -432.82 | -570.05 | -478.87 | -1.36K | -2.54K |
| Normalized Basic EPS | -7.73 | -10.18 | -8.55 | -24.20 | -45.41 |
| EPS Diluted | -434.36 | -575.75 | -478.87 | -1.36K | -2.54K |
| Normalized Diluted EPS | -7.73 | -10.18 | -8.55 | -24.20 | -45.41 |
| Average Basic Shares Outstanding | 186.90K | 144.30K | 144.30K | 60.10K | 28.20K |
| Average Diluted Shares Outstanding | 5.30K | 4.10K | 4.10K | 1.70K | 800.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |